Results for: Ozempic

Lars Fruergaard Jørgensen, CEO of Novo Nordisk, will be questioned by US lawmakers regarding the high prices of the company’s diabetes and weight-loss drugs, including Ozempic and Wegovy. The hearing, scheduled for Tuesday, September 24th, is led by Senator Bernie Sanders who has been critical of the pharmaceutical industry’s pricing practices. Novo Nordisk is expected to defend its pricing, citing high development costs and insurance coverage, while critics point to the company’s significant profits and potential inclusion of their drugs in Medicare’s negotiated pricing program.

Senator Bernie Sanders has renewed his criticism of pharmaceutical giant Novo Nordisk, accusing them of exorbitant pricing for their diabetes drug Ozempic in the United States. He highlighted the stark contrast between the drug’s price in the U.S. compared to other countries, calling out ‘corporate greed’ for the inflated costs. Sanders, who chairs the Senate Health, Education, Labor, and Pensions committee, is actively pushing for a price reduction for Ozempic, a drug that has also gained popularity for weight loss.

Kourtney Kardashian Barker’s wellness brand, Lemme, is launching a plant-based supplement called GLP-1 Daily, marketed as a natural alternative to Ozempic. While experts are skeptical of its effectiveness compared to prescription GLP-1 medications, they acknowledge its potential benefits for regulating blood sugar, fighting visceral fat, and reducing inflammation. The supplement aims to provide a more accessible and natural option for those seeking similar benefits to Ozempic, but without the side effects.

The widespread adoption of Ozempic and similar GLP-1 weight loss drugs has triggered a seismic shift in the fashion and food industries. This article explores how these medications are impacting resale markets, reshaping consumer buying habits, and driving new strategies in the food and beverage sectors.

A US judge’s decision in a multidistrict litigation involving diabetes and weight-loss drugs could significantly impact the course of lawsuits against Novo Nordisk and Eli Lilly. The ruling allows for early resolution of key legal questions, potentially streamlining or halting the litigation before it progresses. The plaintiffs claim the drugs caused gastroparesis, but the companies argue their labels adequately warn of potential gastrointestinal side effects.

A new study published in The Lancet suggests that semaglutide, a drug commonly used for diabetes and weight loss, may significantly reduce the risk of cardiovascular death and worsening heart failure in patients with specific types of heart failure. The analysis, combining data from four clinical trials, found a 31% reduction in combined cardiovascular death or worsening heart failure events in those taking semaglutide.

A new study suggests a possible link between the weight-loss drugs Ozempic and Wegovy and increased suicidal thoughts. The research, published in JAMA Network Open, analyzed data from the World Health Organization and found a higher rate of suicidal ideation associated with semaglutide, the active ingredient in both medications. While the overall rate of suicidal thoughts was small, the researchers recommend further investigation into the potential interaction between semaglutide and psychiatric conditions.

Mounjaro, a new injectable medication, is gaining popularity for its effectiveness in weight loss. While it’s licensed to treat type 2 diabetes, its ability to mimic two hormones makes it more effective than Ozempic and Wegovy. However, the surge in demand for weight loss has led to shortages for diabetics, and experts warn about potential side effects and the importance of lifestyle changes.

A new study suggests a possible link between semaglutide, the active ingredient in Ozempic and Wegovy, and a rare form of blindness called NAION. While the study doesn’t prove causality, it highlights a potential risk that should be discussed with healthcare providers.

Indian pharmaceutical company Biocon is looking for a Chinese partner to conduct clinical trials for generic versions of Novo Nordisk’s blockbuster diabetes drug Ozempic and weight loss treatment Wegovy. The move comes ahead of the patent expiration on semaglutide, a key ingredient in both drugs, in China in 2026.